The fight against cancer has always been a chess match where the disease hides its moves until it is too late. Mercy BioAnalytics, Inc. just raised a $59 million Series B to flip the board in its favor, and the move is as bold as it is calculated. Led by Novalis LifeSciences and Sozo Ventures, with firepower from Perceptive Xontogeny Venture Fund, American Cancer Society BrightEdge, iSelect Fund, Portfolia, Avestria Ventures, Mindshift Capital, and strategic players Hologic, Bruker Scientific, and Labcorp, this syndicate makes one thing clear: the biotech world is watching. Congratulations to Chief Executive Officer Dawn Mattoon, Ph.D., and Chief Scientific Officer Toumy Guettouche, Ph.D., for pushing science and business forward in perfect sync.
Mercy BioAnalytics was founded in 2018 by Paul Blavin and Joseph Sedlak, M.D., Ph.D., on a simple but radical idea: stop chasing scraps of DNA floating in blood like confetti at a crime scene and start decoding the couriers carrying the real messages. Those couriers, extracellular vesicles, are abundant, precise, and present when cancer is still playing its early hand. The Mercy Halo platform takes those signals, amplifies them through immuno-PCR, and makes them readable by instruments already in labs worldwide. This isn’t science fiction, it’s science sharpened into a tool with immediate utility.
The Series B isn’t about dabbling in possibilities. It is fuel for a commercial launch, starting with the ovarian cancer assay, fresh off an FDA Breakthrough Device Designation in July 2025. Ovarian cancer is notorious for silence until late stages. By screening postmenopausal women, Mercy aims to drag the disease into the light early enough to save lives at scale. The roadmap is clear and ambitious: multi-cancer screening trials in 2026 and a lung cancer test in 2027 targeting high-risk smokers. If executed, a single vial of blood could replace uncertainty with clarity, reshaping prevention as we know it.
For a company with fewer than 50 employees, doubling headcount since Series A while locking in partnerships with Labcorp, Hologic, and Bruker Scientific is proof that leverage comes from precision, not payroll. The global liquid biopsy market is set to cross $10 billion by 2028, but Mercy isn’t sprinting for headlines. It’s building the infrastructure for durability: CLIA-certified labs, FDA and CE-Mark approvals, payer engagement, and clinical data strong enough to force the conversation.
The lesson here is sharp: real breakthroughs don’t rely on hype; they hinge on clarity, biological truth, strategic capital, and leadership capable of execution. With Stanley Lapidus chairing the board, a CEO who has carried diagnostics through regulatory finish lines, and investors stacked like a biotech power index, Mercy BioAnalytics isn’t just raising money. It’s raising the standard for how early detection should look, and the industry will not be able to ignore it.
